Fund shareholders of CNS PHARMACEUTICALS INC
ISIN US18978H5081 · United States · LEI 529900FDJ7WGF2Q7UN44
- Fund shareholders
- 2
- Of which ETFs
- 0 2 other funds
- Value held
- 21.5K $
- Share of capital
- 0.5 % of 1.5M shares on Aug 11, 2026
2 tracked funds declare this company. So these figures do not say who owns it.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 6,366 | 19.8K $ | 0.44 % | as of Feb 28, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 555 | 1.7K $ | 0.04 % | as of Feb 28, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 2 | 0 | 6,921 | +267.9 % |
| 2026Q1 | 2 | 0 | 1,881 | +28.4 % |
| 2025Q4 | 2 | 1,465 |
Institutional managers
11 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| Stonepine Capital Management, LLC | 61,000 | 145.8K $ | as of Mar 31, 2026 |
| Ikarian Capital, LLC | 45,830 | 110K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 23,189 | 55.7K $ | as of Mar 31, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 13,524 | 32.3K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 1,310 | 3.1K $ | as of Mar 31, 2026 |
| UBS Group AG | 729 | 1.7K $ | as of Mar 31, 2026 |
| BARRETT & COMPANY, INC. | 8 | 19 $ | as of Mar 31, 2026 |
| MAI Capital Management | 3 | 8 $ | as of Mar 31, 2026 |
| DANSKE BANK A/S | 1 | 2 $ | as of Mar 31, 2026 |
| Caitong International Asset Management Co., Ltd | 1 | 2 $ | as of Mar 31, 2026 |
| CITIGROUP INC | 1 | 2 $ | as of Mar 31, 2026 |
Declared shareholders of CNS PHARMACEUTICALS INC
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Stonepine Capital Management, LLC and 3 others | 9.90 % | 159,790 | as of Mar 31, 2026 · SCHEDULE 13G |
| Ikarian Capital, LLC and 1 other | 5.70 % | 45,830 | as of Dec 31, 2025 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of CNS PHARMACEUTICALS INC". https://titelia.com/en/stocks/cns-pharmaceuticals-inc-US18978H5081